Cencora Inc. (COR)
NYSE: CORHealth CareOther PharmaceuticalsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
COR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $60.54B
- P/E (TTM)
- 23.55
- Forward P/E
- 16.02
- EPS (TTM)
- $13.47
- Dividend yield
- 0.74% ($2.35)
- Ex-dividend date
- Aug 14, 2026
- 52-week range
- 244.82 – 377.54
- Day range
- 315.15 – 322.38
- Volume / Avg
- 1.06M / 1.34M
- Beta
- —
- Shares outstanding
- 190.83M
- Next earnings
- Nov 4, 2026
52-week range
COR stock today
Shares of Cencora (COR) finished higher on Oct 7 at $317.25, a gain of 0.28% or $0.88 per share, versus the S&P 500's 0.22% decline. At this level, COR sits in the middle of its 52-week range of $244.82 to $377.54: 16.0% below the high, set on Nov 25, 2025 and 29.6% above the low. COR is down 6.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 2.8%.
At 23.6x trailing earnings, Cencora trades in line with the peer-group median of 24.2x. Its forward P/E of 16.0x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Cencora's next earnings report is expected on Nov 4, 2026. Cencora pays an annual dividend of $2.35 per share, a 0.74% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Cencora
Company profileCencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S.
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- CEO
- Dr. Robert P. Mauch Ph.D., PharmD
- Headquarters
- Conshohocken, PA
- Employees
- 47,000
- Website
- cencora.com
Financial highlights
Full financialsIn fiscal 2025, Cencora generated $321.33 billion in revenue, up 9.3% from fiscal 2024, its 13th consecutive year of revenue growth. Net income was $1.55 billion (+3.0% year over year), for a net margin of 0.5% versus a median of 0.7% in the prior 5 years. Gross margin was 3.6% (up from 3.4%) and operating margin 0.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $321.33B | $293.96B | $262.17B | $238.59B | $213.99B |
| Growth | +9.31% | +12.12% | +9.89% | +11.50% | +12.69% |
| Net income | $1.55B | $1.51B | $1.75B | $1.70B | $1.54B |
| EPS (diluted) | $7.96 | $7.53 | $8.53 | $8.04 | $7.39 |
Analyst forecast
ForecastConsensus (14 analysts)
buy
Avg. price target
$369.25+16.39%
- Strong buy 4
- Buy 7
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $4.54
- Last reported (Q3 2026)
- Aug 5, 2026
- EPS actual vs est.
- $3.94 vs —
Dividends
Dividend history- Annual dividend
- $2.35
- Dividend yield
- 0.74%
- Last payment
- $0.60
- Ex-dividend date
- Aug 14, 2026
COR news
All COR news- Cencora Remains A Buy At These Prices, As Healthcare Supply-Chain Needs GrowSeeking Alpha
- Invesco S&P 500 Revenue ETF Experiences Big OutflowNasdaqRWL, MCK, CVS, COR
- Here's Why Cencora (COR) is a Strong Growth StockNasdaq
- Notable ETF Inflow Detected - RWL, MCK, COR, CINasdaqRWL, MCK, COR, CI
- Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery?NasdaqCAH, MCK, COR
- Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027Nasdaq
- Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at ConferenceNasdaq
- Here's Why Cencora (COR) is a Strong Value StockNasdaq
Cencora peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CAHCardinal Health Inc. | 232.16 | -0.55% | $53.76B | vs COR |
| MCKMcKesson Corporation | 910.33 | -1.23% | $106.14B | vs COR |
| HLFHerbalife Ltd. | 12.65 | +0.56% | $1.31B | vs COR |
| NUSNu Skin Enterprises Inc. | 4.80 | +1.27% | $233.65M | vs COR |
| ZSTKZeroStack Corp. | 4.77 | +0.42% | $103.97M | vs COR |
| ESYNEnerSyn Global Inc. | 2.06 | -1.90% | $61.24M | vs COR |
| COSMCosmos Health Inc. | 0.3209 | +0.44% | $32.29M | vs COR |
| MEDSDataMeds AI Inc. | 2.88 | -6.19% | $8.16M | vs COR |
Indexes, lists and sector
Index membership
Appears in lists
Cencora stock FAQ
What is Cencora's stock price today?
COR last traded at $317.25 as of Oct 7, 4:00 PM EDT, up 0.28% on the day. Prices are delayed at least 15 minutes.
Does Cencora pay a dividend?
Yes. Cencora pays $2.35 per share annually, a 0.74% yield. The most recent dividend of $0.60 had an ex-dividend date of Aug 14, 2026.
When is Cencora's next earnings date?
Cencora is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $4.54.
What is COR's P/E ratio?
COR trades at a trailing P/E ratio of 23.55 and a forward P/E of 16.02, compared with a median of 24.2 for its closest peers.
Is Cencora in the S&P 500?
Yes. Cencora (COR) is a constituent of the S&P 500 index.
Who is Cencora's CEO?
Dr. Robert P. Mauch Ph.D., PharmD is the chief executive officer of Cencora Inc., which has about 47,000 employees.
Has COR ever split its stock?
Yes. The most recent COR stock split was a 2-for-1 split on Jun 16, 2009, one of 3 splits on record.